This decommissioned ERA site remains active temporarily to support our final migration steps to https://ualberta.scholaris.ca, ERA's new home. All new collections and items, including Spring 2025 theses, are at that site. For assistance, please contact erahelp@ualberta.ca.
Search
Skip to Search Results- 2Immunotherapy
- 2Oncolytic virus
- 2Vaccinia virus
- 1Bladder cancer
- 1Breast cancer
- 1Ribonucleotide reductase
-
Deletion of F4L (ribonucleotide reductase) in Vaccinia Virus Produces a Selective Oncolytic Virus and Promotes Anti-tumor Immunity with Superior Safety in Bladder Cancer
DownloadFall 2017
Overall recurrence of non-muscle-invasive bladder cancer (NMIBC) can be as high as 80% within 5 years of initial treatment. High-grade NMIBC has the greatest risk of recurrence and treatment for these patients includes surgery followed by intravesical therapy with the immunotherapeutic agent...
-
Spring 2021
Vaccinia virus (VACV) has shown promise as an oncolytic agent for treating a variety of tumour types, with preliminary results suggesting that this strategy holds promise for treating breast cancer. Our lab has previously modified VACV by deleting virally-encoded enzymes responsible for dNTP...